NASDAQ:COLL

Collegium Pharmaceutical Competitors

$23.33
+0.30 (+1.30 %)
(As of 04/9/2021 12:00 AM ET)
Add
Compare
Today's Range
$22.81
Now: $23.33
$23.58
50-Day Range
$21.75
MA: $24.09
$26.10
52-Week Range
$15.66
Now: $23.33
$26.91
Volume460,698 shs
Average Volume586,367 shs
Market Capitalization$810.86 million
P/E Ratio47.61
Dividend YieldN/A
Beta1.27

Competitors

Collegium Pharmaceutical (NASDAQ:COLL) Vs. RETA, KRTX, ARVN, ALKS, PCRX, and MOR

Should you be buying COLL stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Collegium Pharmaceutical, including Reata Pharmaceuticals (RETA), Karuna Therapeutics (KRTX), Arvinas (ARVN), Alkermes (ALKS), Pacira BioSciences (PCRX), and MorphoSys (MOR).

Reata Pharmaceuticals (NASDAQ:RETA) and Collegium Pharmaceutical (NASDAQ:COLL) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, valuation, institutional ownership, dividends, risk, analyst recommendations and earnings.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Reata Pharmaceuticals and Collegium Pharmaceutical, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Reata Pharmaceuticals00603.00
Collegium Pharmaceutical11202.25

Reata Pharmaceuticals presently has a consensus price target of $251.25, suggesting a potential upside of 184.16%. Collegium Pharmaceutical has a consensus price target of $25.00, suggesting a potential upside of 7.16%. Given Reata Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts plainly believe Reata Pharmaceuticals is more favorable than Collegium Pharmaceutical.

Profitability

This table compares Reata Pharmaceuticals and Collegium Pharmaceutical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Reata Pharmaceuticals-4,340.72%-163.42%-56.49%
Collegium Pharmaceutical5.71%12.64%3.15%

Valuation and Earnings

This table compares Reata Pharmaceuticals and Collegium Pharmaceutical's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Reata Pharmaceuticals$26.52 million120.70$-290,170,000.00($9.54)-9.27
Collegium Pharmaceutical$296.70 million2.73$-22,720,000.00($0.68)-34.31

Collegium Pharmaceutical has higher revenue and earnings than Reata Pharmaceuticals. Collegium Pharmaceutical is trading at a lower price-to-earnings ratio than Reata Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

64.3% of Reata Pharmaceuticals shares are held by institutional investors. 31.7% of Reata Pharmaceuticals shares are held by insiders. Comparatively, 8.1% of Collegium Pharmaceutical shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Volatility & Risk

Reata Pharmaceuticals has a beta of 1.57, meaning that its stock price is 57% more volatile than the S&P 500. Comparatively, Collegium Pharmaceutical has a beta of 1.27, meaning that its stock price is 27% more volatile than the S&P 500.

Collegium Pharmaceutical (NASDAQ:COLL) and Karuna Therapeutics (NASDAQ:KRTX) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, risk, valuation and analyst recommendations.

Insider and Institutional Ownership

74.8% of Karuna Therapeutics shares are held by institutional investors. 8.1% of Collegium Pharmaceutical shares are held by company insiders. Comparatively, 18.1% of Karuna Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of current recommendations for Collegium Pharmaceutical and Karuna Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Collegium Pharmaceutical11202.25
Karuna Therapeutics001103.00

Collegium Pharmaceutical currently has a consensus target price of $25.00, suggesting a potential upside of 7.16%. Karuna Therapeutics has a consensus target price of $144.70, suggesting a potential upside of 23.77%. Given Karuna Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Karuna Therapeutics is more favorable than Collegium Pharmaceutical.

Profitability

This table compares Collegium Pharmaceutical and Karuna Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Collegium Pharmaceutical5.71%12.64%3.15%
Karuna TherapeuticsN/A-13.91%-13.72%

Risk & Volatility

Collegium Pharmaceutical has a beta of 1.27, indicating that its share price is 27% more volatile than the S&P 500. Comparatively, Karuna Therapeutics has a beta of 2.07, indicating that its share price is 107% more volatile than the S&P 500.

Earnings and Valuation

This table compares Collegium Pharmaceutical and Karuna Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Collegium Pharmaceutical$296.70 million2.73$-22,720,000.00($0.68)-34.31
Karuna TherapeuticsN/AN/A$-43,960,000.00($3.68)-31.77

Collegium Pharmaceutical has higher revenue and earnings than Karuna Therapeutics. Collegium Pharmaceutical is trading at a lower price-to-earnings ratio than Karuna Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Collegium Pharmaceutical beats Karuna Therapeutics on 7 of the 13 factors compared between the two stocks.

Collegium Pharmaceutical (NASDAQ:COLL) and Arvinas (NASDAQ:ARVN) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, earnings, risk, dividends, profitability and analyst recommendations.

Insider & Institutional Ownership

75.7% of Arvinas shares are held by institutional investors. 8.1% of Collegium Pharmaceutical shares are held by company insiders. Comparatively, 11.0% of Arvinas shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of current ratings for Collegium Pharmaceutical and Arvinas, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Collegium Pharmaceutical11202.25
Arvinas00903.00

Collegium Pharmaceutical currently has a consensus target price of $25.00, suggesting a potential upside of 7.16%. Arvinas has a consensus target price of $106.4545, suggesting a potential upside of 67.67%. Given Arvinas' stronger consensus rating and higher possible upside, analysts clearly believe Arvinas is more favorable than Collegium Pharmaceutical.

Profitability

This table compares Collegium Pharmaceutical and Arvinas' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Collegium Pharmaceutical5.71%12.64%3.15%
Arvinas-403.77%-46.99%-35.34%

Volatility & Risk

Collegium Pharmaceutical has a beta of 1.27, indicating that its stock price is 27% more volatile than the S&P 500. Comparatively, Arvinas has a beta of 2.14, indicating that its stock price is 114% more volatile than the S&P 500.

Valuation and Earnings

This table compares Collegium Pharmaceutical and Arvinas' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Collegium Pharmaceutical$296.70 million2.73$-22,720,000.00($0.68)-34.31
Arvinas$42.98 million72.20$-70,290,000.00($2.13)-29.81

Collegium Pharmaceutical has higher revenue and earnings than Arvinas. Collegium Pharmaceutical is trading at a lower price-to-earnings ratio than Arvinas, indicating that it is currently the more affordable of the two stocks.

Alkermes (NASDAQ:ALKS) and Collegium Pharmaceutical (NASDAQ:COLL) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, profitability, dividends, risk and earnings.

Volatility and Risk

Alkermes has a beta of 1.25, suggesting that its stock price is 25% more volatile than the S&P 500. Comparatively, Collegium Pharmaceutical has a beta of 1.27, suggesting that its stock price is 27% more volatile than the S&P 500.

Insider & Institutional Ownership

97.3% of Alkermes shares are held by institutional investors. 4.5% of Alkermes shares are held by insiders. Comparatively, 8.1% of Collegium Pharmaceutical shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares Alkermes and Collegium Pharmaceutical's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alkermes$1.17 billion2.59$-196,620,000.00$0.07271.71
Collegium Pharmaceutical$296.70 million2.73$-22,720,000.00($0.68)-34.31

Collegium Pharmaceutical has lower revenue, but higher earnings than Alkermes. Collegium Pharmaceutical is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Alkermes and Collegium Pharmaceutical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Alkermes-6.28%9.35%5.50%
Collegium Pharmaceutical5.71%12.64%3.15%

Analyst Ratings

This is a breakdown of current ratings and target prices for Alkermes and Collegium Pharmaceutical, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Alkermes16102.00
Collegium Pharmaceutical11202.25

Alkermes currently has a consensus price target of $20.8571, suggesting a potential upside of 9.66%. Collegium Pharmaceutical has a consensus price target of $25.00, suggesting a potential upside of 7.16%. Given Alkermes' higher probable upside, research analysts plainly believe Alkermes is more favorable than Collegium Pharmaceutical.

Summary

Collegium Pharmaceutical beats Alkermes on 9 of the 14 factors compared between the two stocks.

Pacira BioSciences (NASDAQ:PCRX) and Collegium Pharmaceutical (NASDAQ:COLL) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, profitability, dividends, risk and earnings.

Risk & Volatility

Pacira BioSciences has a beta of 1.27, suggesting that its stock price is 27% more volatile than the S&P 500. Comparatively, Collegium Pharmaceutical has a beta of 1.27, suggesting that its stock price is 27% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and target prices for Pacira BioSciences and Collegium Pharmaceutical, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Pacira BioSciences04802.67
Collegium Pharmaceutical11202.25

Pacira BioSciences currently has a consensus price target of $77.50, suggesting a potential upside of 13.55%. Collegium Pharmaceutical has a consensus price target of $25.00, suggesting a potential upside of 7.16%. Given Pacira BioSciences' stronger consensus rating and higher probable upside, research analysts plainly believe Pacira BioSciences is more favorable than Collegium Pharmaceutical.

Earnings and Valuation

This table compares Pacira BioSciences and Collegium Pharmaceutical's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pacira BioSciences$421.03 million7.11$-11,020,000.00$0.8679.36
Collegium Pharmaceutical$296.70 million2.73$-22,720,000.00($0.68)-34.31

Pacira BioSciences has higher revenue and earnings than Collegium Pharmaceutical. Collegium Pharmaceutical is trading at a lower price-to-earnings ratio than Pacira BioSciences, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Pacira BioSciences and Collegium Pharmaceutical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Pacira BioSciences29.95%10.71%4.88%
Collegium Pharmaceutical5.71%12.64%3.15%

Summary

Pacira BioSciences beats Collegium Pharmaceutical on 9 of the 11 factors compared between the two stocks.

Collegium Pharmaceutical (NASDAQ:COLL) and MorphoSys (NASDAQ:MOR) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, valuation, risk, dividends, profitability and analyst recommendations.

Profitability

This table compares Collegium Pharmaceutical and MorphoSys' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Collegium Pharmaceutical5.71%12.64%3.15%
MorphoSys8.76%4.51%2.25%

Insider & Institutional Ownership

3.1% of MorphoSys shares are owned by institutional investors. 8.1% of Collegium Pharmaceutical shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Collegium Pharmaceutical and MorphoSys, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Collegium Pharmaceutical11202.25
MorphoSys06402.40

Collegium Pharmaceutical presently has a consensus price target of $25.00, suggesting a potential upside of 7.16%. Given Collegium Pharmaceutical's higher probable upside, equities research analysts clearly believe Collegium Pharmaceutical is more favorable than MorphoSys.

Valuation & Earnings

This table compares Collegium Pharmaceutical and MorphoSys' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Collegium Pharmaceutical$296.70 million2.73$-22,720,000.00($0.68)-34.31
MorphoSys$80.43 million36.57$-115,380,000.00($0.91)-24.57

Collegium Pharmaceutical has higher revenue and earnings than MorphoSys. Collegium Pharmaceutical is trading at a lower price-to-earnings ratio than MorphoSys, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Collegium Pharmaceutical has a beta of 1.27, suggesting that its stock price is 27% more volatile than the S&P 500. Comparatively, MorphoSys has a beta of 1.03, suggesting that its stock price is 3% more volatile than the S&P 500.

Summary

Collegium Pharmaceutical beats MorphoSys on 8 of the 14 factors compared between the two stocks.


Collegium Pharmaceutical Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Reata Pharmaceuticals logo
RETA
Reata Pharmaceuticals
1.4$88.42+7.3%$3.20 billion$26.52 million-7.79Unusual Options Activity
Gap Down
Karuna Therapeutics logo
KRTX
Karuna Therapeutics
1.6$116.91+0.9%$3.16 billionN/A-58.16News Coverage
Arvinas logo
ARVN
Arvinas
1.5$63.49+1.5%$3.10 billion$42.98 million-24.80Insider Selling
Alkermes logo
ALKS
Alkermes
1.2$19.02+0.2%$3.03 billion$1.17 billion-41.35Unusual Options Activity
Pacira BioSciences logo
PCRX
Pacira BioSciences
2.0$68.25+0.4%$2.99 billion$421.03 million24.03Analyst Downgrade
Analyst Revision
Gap Down
MorphoSys logo
MOR
MorphoSys
0.3$22.36+0.8%$2.94 billion$80.43 million106.48Analyst Report
Organogenesis logo
ORGO
Organogenesis
1.0$22.84+4.9%$2.92 billion$260.98 million-380.67Gap Up
Viela Bio logo
VIE
Viela Bio
0.8$53.01+0.0%$2.91 billion$50 million-7.55
OPKO Health logo
OPK
OPKO Health
1.9$4.18+2.2%$2.80 billion$901.90 million-23.22
Taro Pharmaceutical Industries logo
TARO
Taro Pharmaceutical Industries
1.1$72.83+0.2%$2.79 billion$644.77 million-10.39Analyst Upgrade
Corcept Therapeutics logo
CORT
Corcept Therapeutics
1.5$22.68+1.0%$2.66 billion$306.49 million25.48Insider Selling
Intra-Cellular Therapies logo
ITCI
Intra-Cellular Therapies
1.7$31.69+0.6%$2.56 billion$60,000.00-9.84News Coverage
ALX Oncology logo
ALXO
ALX Oncology
1.9$63.77+13.2%$2.56 billionN/A0.00Analyst Report
Gap Down
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.6$153.44+1.4%$2.55 billion$120.28 million-154.99Analyst Upgrade
News Coverage
Global Blood Therapeutics logo
GBT
Global Blood Therapeutics
1.4$40.77+1.1%$2.53 billion$2.11 million-8.82Analyst Upgrade
News Coverage
Deciphera Pharmaceuticals logo
DCPH
Deciphera Pharmaceuticals
1.6$43.81+1.4%$2.52 billion$25 million-8.76Insider Selling
News Coverage
Rocket Pharmaceuticals logo
RCKT
Rocket Pharmaceuticals
1.4$39.41+8.7%$2.43 billionN/A-21.65News Coverage
Gap Down
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.6$9.19+0.9%$2.43 billion$182.24 million-7.99News Coverage
Cryoport logo
CYRX
Cryoport
1.9$52.29+3.1%$2.38 billion$33.94 million-90.16Insider Selling
News Coverage
Gap Down
Xencor logo
XNCR
Xencor
1.2$40.47+2.9%$2.35 billion$156.70 million-28.91News Coverage
Gap Down
Amarin logo
AMRN
Amarin
1.6$5.93+1.2%$2.33 billion$429.76 million-118.58
Arcus Biosciences logo
RCUS
Arcus Biosciences
2.0$31.30+1.3%$2.22 billion$15 million-16.39
Prestige Consumer Healthcare logo
PBH
Prestige Consumer Healthcare
1.6$43.75+0.5%$2.18 billion$963.01 million13.59Analyst Upgrade
News Coverage
IGM Biosciences logo
IGMS
IGM Biosciences
1.7$68.49+16.4%$2.10 billionN/A-29.14Insider Selling
Gap Down
Revance Therapeutics logo
RVNC
Revance Therapeutics
1.7$28.13+1.4%$2.01 billion$410,000.00-6.12
Dicerna Pharmaceuticals logo
DRNA
Dicerna Pharmaceuticals
1.8$26.09+1.3%$1.99 billion$23.90 million-16.20Analyst Revision
News Coverage
Axsome Therapeutics logo
AXSM
Axsome Therapeutics
1.4$52.99+2.1%$1.98 billionN/A-19.70
NGM Biopharmaceuticals logo
NGM
NGM Biopharmaceuticals
1.8$25.43+3.8%$1.95 billion$103.54 million-19.12Gap Down
MORF
Morphic
1.1$59.35+3.0%$1.93 billion$16.98 million-38.04Insider Selling
Gap Down
Kura Oncology logo
KURA
Kura Oncology
1.6$28.57+0.8%$1.89 billionN/A-17.53
Seres Therapeutics logo
MCRB
Seres Therapeutics
1.7$20.58+0.1%$1.88 billion$34.51 million-17.59News Coverage
Madrigal Pharmaceuticals logo
MDGL
Madrigal Pharmaceuticals
1.7$117.02+0.4%$1.88 billionN/A-10.57
MacroGenics logo
MGNX
MacroGenics
1.2$31.16+1.3%$1.87 billion$64.19 million-9.96
Amneal Pharmaceuticals logo
AMRX
Amneal Pharmaceuticals
1.6$5.96+2.7%$1.79 billion$1.63 billion14.54News Coverage
Pandion Therapeutics logo
PAND
Pandion Therapeutics
1.0$60.05+0.0%$1.77 billion$970,000.000.00
Five Prime Therapeutics logo
FPRX
Five Prime Therapeutics
1.4$37.94+0.1%$1.77 billion$14.87 million-14.16News Coverage
Applied Molecular Transport logo
AMTI
Applied Molecular Transport
2.0$48.93+21.0%$1.72 billionN/A0.00Insider Buying
Gap Down
Cytokinetics logo
CYTK
Cytokinetics
1.7$24.16+0.1%$1.72 billion$26.87 million-12.65
FibroGen logo
FGEN
FibroGen
1.8$18.57+1.3%$1.70 billion$256.58 million-7.11Analyst Downgrade
Unusual Options Activity
Analyst Revision
News Coverage
Cassava Sciences logo
SAVA
Cassava Sciences
0.9$41.57+1.3%$1.66 billionN/A-173.21
ADC Therapeutics logo
ADCT
ADC Therapeutics
1.7$23.99+7.6%$1.65 billion$2.34 million-10.17Gap Down
Myovant Sciences logo
MYOV
Myovant Sciences
1.3$18.15+1.2%$1.65 billionN/A-6.46Insider Selling
Prelude Therapeutics logo
PRLD
Prelude Therapeutics
1.4$35.26+6.0%$1.64 billionN/A0.00Insider Selling
News Coverage
Gap Down
Ironwood Pharmaceuticals logo
IRWD
Ironwood Pharmaceuticals
1.8$10.19+1.5%$1.64 billion$428.41 million14.77
Aurinia Pharmaceuticals logo
AUPH
Aurinia Pharmaceuticals
1.8$12.80+1.3%$1.63 billion$320,000.00-8.71News Coverage
Harmony Biosciences logo
HRMY
Harmony Biosciences
1.4$28.32+0.2%$1.61 billionN/A0.00
Travere Therapeutics logo
TVTX
Travere Therapeutics
1.2$25.61+1.4%$1.55 billion$175.34 million-15.06
Zentalis Pharmaceuticals logo
ZNTL
Zentalis Pharmaceuticals
1.8$37.41+13.5%$1.54 billionN/A0.00Insider Selling
Gap Down
Generation Bio logo
GBIO
Generation Bio
1.8$27.20+5.3%$1.53 billionN/A0.00Insider Selling
News Coverage
Gap Down
Kronos Bio logo
KRON
Kronos Bio
1.7$27.28+0.3%$1.53 billionN/A0.00Lockup Expiration
This page was last updated on 4/10/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.